Agios Pharm

NASDAQ AGIO

Download Data

Agios Pharm Capital Expenditure To Sales 1 year YoY Change (%) for the quarter ending March 31, 2024: -75.80%

Agios Pharm Capital Expenditure To Sales 1 year YoY Change (%) is -75.80% for the quarter ending March 31, 2024, a 22.57% change year over year. The capital expenditure ratio measures the proportion of a company's revenue allocated to capital expenditures. It is calculated by dividing capital expenditures by revenue. This ratio indicates the extent to which a company invests in long-term assets relative to its sales. A higher ratio suggests a higher level of investment in the expansion and improvement of the company's asset base. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Agios Pharm Capital Expenditure To Sales for the quarter ending March 31, 2023 was 7.11%, a -97.89% change year over year.
  • Agios Pharm Capital Expenditure To Sales for the quarter ending March 31, 2022 was 337.02%, a 13,690.15% change year over year.
  • Agios Pharm Capital Expenditure To Sales for the quarter ending March 31, 2021 was 2.44%, a -52.22% change year over year.
  • Agios Pharm Capital Expenditure To Sales for the quarter ending March 31, 2020 was 5.11%, a -24.14% change year over year.
NASDAQ: AGIO

Agios Pharm

CEO Dr. Bruce D. Car DACVP, Ph.D.
IPO Date July 24, 2013
Location United States
Headquarters 88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees 383
Sector Healthcare
Industry Biotechnology
Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

COGT

Cogent Biosciences Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

KALV

Kalvista Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email